Nexavar Bayer | search
Click here to view Nexavar Bayer news from 60+ newspapers.
Bookmark or Share- Sorafenib - WikipediaSorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
- NEXAVAR (NEX-A-VAR) (sorafenib) tablets, oral What is NEXAVAR?NEXAVAR is a prescription medicine used to treat: • a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed by surgery • a type of kidney cancer called renal cell carcinoma (RCC)
- NEXAVAR 200 Film-coated Tablets - BayerPHARMACOLOGICAL ACTION: Pharmacodynamic properties: Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-3, and PDGFR-ß).
- NDA 021923 Nexavar FDA Approved 19 Jun 2020NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment. 2 DOSAGE AND ADMINISTRATION
- PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION - BayerApproval of NEXAVAR for locally advanced/metastatic Renal Cell (clear cell) Carcinoma (RCC) is based on progression-free survival (PFS) in low and intermediate risk (MSKCC prognostic criteria) patients without brain metastasis.
More
